Clinical Trial Update: Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

This update reports on a Phase 1 trial of ADI-PEG 20 plus doxorubicin in patients with HER2-negative metastatic breast cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Polaris Group | Conditions: HER2 Negative Metastatic Breast Cancer | Phase 1 | Status: COMPLETED